Document:

Exhibit 10.10

 

CONFIDENTIAL MATERIAL OMITTED AND FILED
 SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
 DOUBLE ASTERISKS DENOTE SUCH OMISSIONS.

 

THIRD AMENDMENT TO DEFINITIVE AGREEMENT

 

This Third Amendment to Agreement, effective January 15, 2013, is by and between THE LEUKEMIA & LYMPHOMA SOCIETY (“LLS”), a Delaware corporation, business at 1311 Mamaroneck Ave, White Plains, NY and ONCONOVA THERAPEUTICS (“ONCONOVA”), a Delaware corporation having its principal place of business at 375 Pheasant Run, Newtown, PA.

 

WHEREAS, LLS and ONCONOVA have previously entered into an agreement to conduct a human clinical trial entitled “Approval Track Clinical Trial of ON 01910.Na in High Risk Myelodysplastic Syndromes (MDS) Patients Refractory to Hypomethylating Agents, an Unmet Medical Need” effective May 12, 2010 as amended on June 23, 2011 and May 29, 2012 (collectively the “Agreement”) under which LLS supports clinical research conducted by ONCONOVA with the goal of successfully completing a pivotal trial; and

 

WHEREAS, an Amendment is sought to reflect payment changes in Section 10.1 due to Onconova’s pending termination of further Funding from LLS and to add a member from LLS to the Research Advisory Committee in order for LLS to have bi-annual updates on the success of the Research Program.

 

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants hereinafter set forth; it is agreed by LLS and ONCONOVA that the following applies:

 

1.             Terms not otherwise defined herein shall have the meanings given them in the Agreement;

 

2.             The second sentence of Section 2.1 of the Agreement is modified to read in its entirety as follows:

 

“The sum total of the Funding shall not exceed $8,000,000 and shall be paid in accordance with the amounts and achievement of Milestones set forth in Revised Exhibit C.”

 

3.             Section 10.1(a) of the Agreement is modified to read in its entirety as follows:

 

“if Company partners or outlicenses the rights to the Product to a third party or transfers the rights to the Product to a partnership with a third party for further development and/or commercialization of the Product (a “Product Outlicense”), then Company shall pay to LLS payments under the following tiered payment schedule: (i) an amount equal to ** payable upon execution of the Product Outlicense; (ii) an amount equal to ** within ** days after the first approval for market registration by a regulatory body; (iii) an amount equal to ** within ** days after the First Commercial Sale; (iv) an amount equal to ** within **

 

1

 

days after meeting the sales milestone of ** in Net Sales; and (v) a royalty equal to ** of Net Sales starting from the date of the First Commercial Sale. The Parties acknowledge that Company has entered into a License Agreement, dated July 5, 2011, with SymBio Pharmaceuticals Limited and that such License Agreement does not constitute a Product Outlicense for purposes of clause (i) of this Section 10.1.”

 

4.             Section 10.1(d) of the Agreement is modified in its entirety as follows:

 

“if Company combines through merger or otherwise with another company, is sold or transferred to another company or all or substantially all of its assets relating to the Product are sold or transferred to another company (each, a “Company Sale”), and only if the counterparty to the Company Sale does not assume all of the Company’s obligations under Sections 10.1(a) and (b), Company shall pay to LLS or cause such other company to pay to LLS, subject to Section 10.1(e), (i) an amount equal to ** within ** days after the first regulatory approval for marketing of the Product by a regulatory body; (ii) an amount equal to ** within ** days of the First Commercial Sale; (iii) an amount equal to ** within ** days of meeting the sales milestone of ** in annual Net Sales; and (iv) a royalty equal to ** of Net Sales. LLS agrees to consider in good faith any proposal from Company or its successor for a lump sum payment in lieu of such royalty.”

 

5.             Section 10.1 (e) of the Agreement is modified as follows:

 

“The payments specified in each of clauses (a), (b), (c), and (d) of the agreement, are mutually exclusive and in no event shall Company be required to make, and LLS shall not be entitled to receive, payments under more than any one of such clauses at any given time. The aggregated total payments to LLS under this Section 10.1, notwithstanding any other provision of this Agreement to the contrary, shall be limited to up to ** times the total Funding actually received by Company from LLS under this Agreement and said aggregated total payments to LLS from Company may not exceed **.”

 

6.             Research Advisory Committee: At termination of the Definitive Agreement, the Parties agree to retain the Research Advisory Committee and the working relationship established. The Parties agree to meet in person or by phone on at least a bi-annual basis to provide updates on the Product development and commercialization efforts of the Product until all contract obligations are completed.

 

2

 

7.             Except as expressly amended or supplemented by this Amendment to the Agreement, all of the terms and conditions of the Agreement shall remain in full force and effect in accordance with their terms.

 

8.             Revised Exhibit C of the Second Amendment effective May 29, 2012 is hereby replaced in its entirety by Revised Exhibit C attached hereto.

 

9.             No agreement or understanding bearing on this Amendment to the Agreement shall be binding on either party hereto unless it shall be in writing and signed and delivered by a duly authorized officer or representative of each of LLS and ONCONOVA expressly referring to this Amendment to the Agreement.

 

IN WITNESS WHEREOF, the parties have caused the Amendment to be executed and delivered by their duly authorized representatives.

 

	
THE   LEUKEMIA & LYMPHOMA SOCIETY
    	
 
    	
ONCONOVA   THERAPEUTICS, INC.
    
	
 
    	
 
    	
 
    
	
By:
    	
James   T. Nangle
    	
 
    	
By:
    	
Ramesh   Kumar, Ph.D.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
(Signature)
    	
/s/   James T. Nangle
    	
 
    	
(Signature)
    	
/s/   Ramesh Kumar, Ph.D.
    
	
Title:
    	
Senior   Vice President & CFO
    	
 
    	
Title:
    	
President   and CEO
    

 

3

 

REVISED EXHIBIT C

 

Deliverables, Milestones and Payments

 

LLS and Company agree to the following provisions regarding timelines, Deliverables, Milestones and Payments in performance of the Research Program under the terms of the Agreement.

 

1.             Timelines.

 

1.1. Definition. A timeline is a linear, chronological representation of key events or steps along the Term of this Agreement whereby the Parties measure progress toward the goals of the Research Program. The timeline is a pictorial representation of the anticipated Deliverables, Milestones and Payments to Company by LLS.

 

1.2. Overview of Research Program Timeline. The following timeline represents the Company’s best estimate for achieving site initiation, follow-up and study reports. In order to maintain maximum flexibility of the Research Program, the timeline and associated Deliverables, Milestones and Payments may be revised by mutual agreement of the Parties.

 

Timeline for Site Initiation, Follow-up, and Study Report for Approval Track Clinical Trial of ON 01910.Na in High Risk Myelodysplastic Syndromes (MDS) Patients Refractory to Hypomethylating Agents.

 

1.3. Timeline of Deliverables, Milestones and Payments. The Parties agree that the following is a representation of key events during the Term of this Agreement, whereby Deliverables, Milestones and Payments are represented by single letter designations (“D”, “M”, and “P”, respectively). Numbers that follow the single letter designations represent the consecutive order of the Deliverables, Milestones or Payments.

 

2.             Deliverables.

 

2.1. Research Program Deliverables. The Parties have agreed upon the following defined Deliverables.

 

	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    

 

4

 

	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    

 

3.             Milestones and Payments.

 

3.1. Definition. A Milestone is a readily identifiable and quantifiable achievement reflecting progress in the Research Program. A Payment is the transfer of Funding from LLS to Company.

 

3.2. Research Program Payments and Milestones. The following schedule of Payments, which were subject to the achievement of Milestones, have been received for a total of $8 Million dollars.

 

	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    
	
**
    	
**
    	
**
    

 

4.             Research Advisory Committee Meetings.

 

4.1. Research Advisory Committee Meeting Schedule. The Parties have tentatively agreed upon a schedule of Research Advisory Committee Meetings. In accordance with Article 3.2 of the Agreement, additional meetings may be scheduled and the Team Leaders, upon mutual agreement, may change such meeting dates.

 

	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    

 

5

 

	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    
	
**
    	
**
    

 

6Exhibit 10.11

 

TERMINATION OF AGREEMENT

 

This Termination of Agreement, effective February 5, 2013, is by and between THE LEUKEMIA & LYMPHOMA SOCIETY (“LLS”), a Delaware corporation, having its principal place of business at 1311 Mamaroneck Ave, White Plains, NY and ONCONOVA THERAPEUTICS (“ONCONOVA,” together “the Parties”), a Delaware corporation having its principal place of business at 375 Pheasant Run, Newtown, PA.

 

WHEREAS, LLS and ONCONOVA have previously entered into an agreement to conduct a human clinical trial entitled “Approval Track Clinical Trial of ON 01910.Na in High Risk Myelodysplastic Syndromes (MDS) Patients Refractory to Hypomethylating Agents, an Unmet Medical Need” effective May 12, 2010 as amended on June 23, 2011, May 1, 2012 and January 15 , 2013 (collectively the “Agreement”) under which LLS supports clinical research conducted by ONCONOVA with the goal of successfully completing a pivotal trial; and

 

WHEREAS, a Third Amendment to Agreement was executed on January 15, 2013, to reflect payment changes in Section 10.1 due to Onconova’s pending termination of further Funding from LLS and to add a member from LLS to the Development Committee in order for LLS to have bi-annual updates on the success of the Research Program; and

 

WHEREAS, LLS and ONCONOVA wish to terminate the further funding and the Agreement,

 

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants hereinafter set forth, it is agreed by LLS and ONCONOVA that the following applies:

 

1.                                      Terms not otherwise defined herein shall have the meanings given them in the Agreement;

 

2.                                      The parties hereby agree to terminate the Agreement in accordance with Section 15.2 of the Agreement. The termination date of the Agreement shall be thirty (30) days from the effective date of this Termination of Agreement.

 

3.                                      Except as expressly amended or supplemented by this Termination of Agreement, all of the terms and conditions of the Agreement shall remain in full force and effect in accordance with their terms.

 

4.                                      No agreement or understanding bearing on this Termination of Agreement shall be binding on either party hereto unless it shall be in writing and signed and delivered by a duly authorized officer or representative of each of LLS and ONCONOVA expressly referring to this Termination of Agreement.

 

 

IN WITNESS WHEREOF, the parties have caused the Amendment to be executed and delivered by their duly authorized representatives.

 

	
THE   LEUKEMIA & LYPHOMA SOCIETY
    	
 
    	
ONCONOVA   THERAPUETICS, INC.
    
	
By:
    	
Richard   Winneker, Ph.D.
    	
 
    	
By:
    	
Ramesh   Kumar, Ph.D.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
(Signature)
    	
/s/   Richard Winneker, Ph.D.
    	
 
    	
(Signature)
    	
/s/   Ramesh Kumar, Ph.D.
    
	
Title:
    	
Senior   Vice President, Research
    	
 
    	
Title:   
    	
President   and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]